Tag: TRI CCA

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis...

SAN FRANCISCO, June 23, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsTRI CCA

New Product Safety Recalls

Adecoagro And Tether To Power Bitcoin Mining With Renewable Energy In Brazil

$5 Bn Pet Supplements Market Trends, Analysis, and Forecasts 2025-2034 | AI-Driven Personalized Nutrition and CBD-Infused Supplements Transforming Pet Health

Tag: TRI CCA

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis...

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us